Table 5.
Table 5 Incidence of metabolic (MetS) in people with schizophrenia
| Study | Country | N | Design | Mean age | % MetS | Criteria |
| De Hert et al (71) | Belgium | 31 | Baseline aripiprazole | 36.7 | 61.3 | ATP III-A |
| Endpoint aripiprazole | 36.7 | 29.0 | ATP III-A | |||
| Attux et al (64) | Brazil | 44 | First episode 6 months | 26.3 | 6.8 | ATP III |
| De Hert et al (73) | Belgium | 155 | After 3 months SGA | 33.7 | 18.7 | ATP III-A |
| 16 | After 3 months amisulpride | 33.7 | 6.3 | ATP III-A | ||
| 16 | After 3 months aripiprazole | 33.7 | 0.0 | ATP III-A | ||
| 20 | After 3 months clozapine | 33.7 | 45.0 | ATP III-A | ||
| 45 | After 3 months olanzapine | 33.7 | 24.4 | ATP III-A | ||
| 21 | After 3 months quetiapine | 33.7 | 19.1 | ATP III-A | ||
| 37 | After 3 months risperidone | 33.7 | 10.8 | ATP III-A | ||
| L’Italien et al (79) | USA | 91 | Placebo trials, placebo | 41.4 | 14.3 | ATP III |
| 151 | Placebo trials, aripiprazole | 40.7 | 5.3 | ATP III | ||
| 212 | Active comparator trials, olanzapine | 37.7 | 27.4 | ATP III | ||
| 198 | Active comparator trials, aripiprazole | 37.6 | 15.7 | ATP III | ||
| Saddichha et al (89) | India | 30 | First episode 6 weeks | 26.9 | 27.5 | IDF |
| Srisurapanont et al (95) | Thailand | 35 | Naturalistic 1 year follow-up | 34.7 | 20.0 | IDF |
| De Hert et al (74) | Belgium | 122 | First episode, 3 year FGA | 26.8 | 9.8 | ATP III-A |
| 108 | First episode, 3 year SGA | 25.1 | 27.8 | ATP III-A | ||
| 8 | First episode, 3 year amisulpride | 25.1 | 12.5 | ATP III-A | ||
| 10 | First episode, 3 year aripiprazole | 25.1 | 0.0 | ATP III-A | ||
| 12 | First episode, 3 year clozapine | 25.1 | 50.0 | ATP III-A | ||
| 34 | First episode, 3 year olanzapine | 25.1 | 41.3 | ATP III-A | ||
| 24 | First episode, 3 year quetiapine | 25.1 | 12.6 | ATP III-A | ||
| 20 | First episode, 3 year risperidone | 25.1 | 10.2 | ATP III-A | ||
| Meyer et al (84) | USA | 164 | Baseline olanzapine | 40.9 | 34.8 | ATP III-A |
| After 3 months olanzapine | 40.9 | 43.9 | ATP III-A | |||
| 147 | Baseline risperidone | 40.9 | 30.6 | ATP III-A | ||
| After 3 months risperidone | 40.9 | 30.6 | ATP III-A | |||
| 143 | Baseline quetiapine | 40.9 | 37.8 | ATP III-A | ||
| After 3 months quetiapine | 40.9 | 37.1 | ATP III-A | |||
| 77 | Baseline ziprasidone | 40.9 | 37.7 | ATP III-A | ||
| After 3 months ziprasidone | 40.9 | 29.9 | ATP III-A | |||
| 129 | Baseline perphenazine | 40.9 | 37.2 | ATP III-A | ||
| After 3 months perphenazine | 40.9 | 38.0 | ATP III-A | |||
| Schorr et al (93) | Netherlands | 260 | 12 months incidence | 41.0 | 14.0 | ATP III |
| 12 months reversibility | 37.0 | 33.0 | ATP III |